Imeik announced on September 28 that its wholly owned subsidiary Beijing Nuobote Biotechnology Co., Ltd. recently received the Drug Registration Certificate for lidocaine and tetracaine cream approved and issued by the National Medical Products Administration. The drug is a prescription medicine indicated for intact skin in adults, mainly for local analgesia, with specific indications including dermal filler injections, pulsed dye laser treatment and other medical aesthetics procedures. In the first half of 2026, Imeik achieved revenue of 1.216 billion yuan and net profit attributable to the parent company of 593 million yuan.
Imeik Technology Development CoWholly owned subsidiary received NMPA Drug Registration Certificate for lidocaine and tetracaine cream, expanding its medical aesthetics product portfolio.
